Differences and commonalities in the management of locally advanced prostate cancer: Results from a survey of oncologists and urologists in the UK

BJU International

Volumn 99, Issue 3, 2007, Pages 545-553

  Payne, Heather A ^a   Gillatt, David A ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Locally advanced prostate cancer; Oncologists; Survey; UK; Urologists

Indexed keywords

GONADORELIN ANTAGONIST;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; HEALTH SURVEY; HUMAN; MEDICAL SPECIALIST; NORMAL HUMAN; ONCOLOGY; PATIENT CARE; POSTAL MAIL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUESTIONNAIRE; TREATMENT DURATION; UNITED KINGDOM; UROLOGY;

GREAT BRITAIN; HEALTH SURVEYS; HUMANS; MALE; MEDICAL ONCOLOGY; PROFESSIONAL PRACTICE; PROSTATIC NEOPLASMS; QUESTIONNAIRES; UROLOGY;

EID: 33846926803     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06651.x     Document Type: Article

References (22)

1. Cancer Research UK. UK Prostate Cancer mortality statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/prostate/?a= 5441. Accessed October 2006
2. American Joint Committee on Cancer. Prostate. AJCC Cancer Staging Manual, 6th edn. New York, NY: Springer 2002: 309-16
3. BAUS, BUG, BPG. MDT (Multidisciplinary Team). Guidance for Managing Prostate Cancer. 2005 Guidance Available from Authors
4. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74
5. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8
6. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8
7. Zelefsky MJ, Leibel SA, Burman CM et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostate cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncon Biol Phys 1994; 29: 755-61
8. Henderson A, Langley SE, Laing RW. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol (R Coll Radiol) 2003; 15: 318-21
9. Hara I, Miyake H, Yamada Y et al. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate. Int J Urol 2002; 9: 322-8
10. Linberg R, Conover CD, Shum KL, Shorr RG. Increased tissue oxygenation and enhanced radiation sensitivity of solid tumors in rodents following polyethylene glycol conjugated bovine hemoglobin administration. In Vivo 1998; 12: 167-73
11. Pilepich MV, Winter K, John MJ et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52
12. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6
13. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90
14. Hanks GE, Pajak TF, Porter A et al.; Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-8
15. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247-54
16. Dearnaley DP, Khoo VS, Norman AR et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353: 267-72
17. Pollack A, Zagars GK, Starkschall G et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097-105
18. Zelefsky MJ, Fuks Z, Hunt M et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166: 876-81
19. Dearnaley DP, Hall E, Lawrence D et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005; 92: 488-98
20. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52: 6-13
21. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: what is it, really? Radiother Oncol 2005; 76: 1-3
22. Livsey JE, Cowan RA, Wylie JP et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 2003; 57: 1254-9